Study wrapper · #996
A cluster analysis of 466 patients demonstrates that glutathione supplementation could preferentially benefit advanced unstable cirrhosis phenotype rather than stable cirrhosis.
Philips CA, Sreemohan A, Baby A, et al. Frontiers in pharmacology. 2026.
DOI: 10.3389/fphar.2026.1767206PubMed: 42453576
Editor's note
A retrospective cohort using clustering rather than a controlled trial, so causal conclusions are limited. Glutathione is the direct subject, associated with benefit only in a specific high-risk phenotype while the overall population showed worsened MELD scores. Hypothesis-generating, needing prospective validation.
Plain-language abstract
In a retrospective study of 466 people with chronic liver disease, oral glutathione was associated with improvement mainly in a subgroup with advanced, inflammation-driven cirrhosis, while the overall group worsened.
Related coverage
Weak / none
Preconditioning and supplementation with glutathione ameliorates oxidative stress, mitochondrial dysfunction, and restores metabolic imbalance in insulin-resistant myotubes.
Biochemical and biophysical research communicationsn=——2026
Mixed
A review of the potential benefits and limitations of oral glutathione supplementation.
Inflammopharmacologyn=——2026
Mixed
Efficacy and Safety of Glutathione Supplementation in Type 2 Diabetes & Diabetes Complications.
Nutrientsn=——2026